Jasper Therapeutics
Clinical-stage biotechnology company focused on developing monoclonal antibody therapies that deplete mast cells via inhibition of KIT signaling. The company advances preclinical and clinical programs (including Phase 1/1b/2a studies) for mast cell–driven diseases and maintains proprietary preclinical models and a publication record of in vivo and clinical pharmacology studies.
Industries
Nr. of Employees
medium (51-250)
Jasper Therapeutics
Redwood City, California, United States, North America
Products
Briquilimab
Humanized, aglycosylated monoclonal antibody that blocks SCF binding to the KIT receptor to inhibit KIT signaling and induce mast cell apoptosis; being evaluated for mast cell–driven diseases.
KP-104
Pipeline bifunctional complement-targeted biologic under evaluation for complement-mediated and nephrology disorders.
KP-701
Pipeline antibody program targeting B-cell related mechanisms for autoantibody-mediated disorders.
Briquilimab
Humanized, aglycosylated monoclonal antibody that blocks SCF binding to the KIT receptor to inhibit KIT signaling and induce mast cell apoptosis; being evaluated for mast cell–driven diseases.
KP-104
Pipeline bifunctional complement-targeted biologic under evaluation for complement-mediated and nephrology disorders.
KP-701
Pipeline antibody program targeting B-cell related mechanisms for autoantibody-mediated disorders.
Expertise Areas
- Monoclonal antibody therapeutics
- Mast cell biology and targeted depletion strategies
- Preclinical animal models and translational in vivo pharmacology
- Early-phase clinical trial management (Phase 1/1b/2a)
Key Technologies
- Monoclonal antibody engineering
- Aglycosylated antibody formats
- KIT (CD117) receptor targeting
- Humanized/chimeric mouse models for KIT testing
News & Updates
Conference poster reporting NHP safety/tolerability and tissue mast cell depletion following administration of a KIT-targeting antibody.
Trial-in-progress poster describing an ongoing Phase 1b/2a study of a KIT-targeting antibody in chronic inducible urticaria.
Trial-in-progress presentation describing an ongoing Phase 1b/2a study in chronic spontaneous urticaria.
Presentation reporting durable remissions in older adults with AML in complete remission and MDS undergoing allogeneic hematopoietic cell transplantation following antibody-based conditioning.
Conference poster reporting NHP safety/tolerability and tissue mast cell depletion following administration of a KIT-targeting antibody.
Trial-in-progress poster describing an ongoing Phase 1b/2a study of a KIT-targeting antibody in chronic inducible urticaria.
Trial-in-progress presentation describing an ongoing Phase 1b/2a study in chronic spontaneous urticaria.
Presentation reporting durable remissions in older adults with AML in complete remission and MDS undergoing allogeneic hematopoietic cell transplantation following antibody-based conditioning.